High Alert
Antibiotics in the clinical pipeline in 2011
Butler MS et al. – The emergence of multi–drug–resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. read more
Most Recent Posts
Staphylococcal decolonisation: an effective strategy for prevention of infection?
Simor AE – The efficacy of decolonisation of patients with community–associated MRSA has not been established, and the routine use of decolonisation of non–surgical patients is not supported by data. read more
New Gram-positive antibiotics: better than vancomycin?
Van Hal SJ et al. – Based on current evidence, greater microbiological and clinical cure rates are achieved with alternative agents. However, these differences do not translate into mortality benefits compared with vancomycin for the treatment of Staphylococcus aureus infections. read more
The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia
Honda H et al. – Among patients with MRSA bacteremia treated with vancomycin, reduced vancomycin susceptibility and vancomycin tolerance were not associated with mortality after adjusting for patient factors. Patient factors including severity of illness and underlying co–morbidities were associated with the mortality. read more
A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition
Suarez C et al. – In the setting of sustained multiresistant Pseudomonas aeruginosa outbreaks, epidemiological findings suggest that patients may be a reservoir for further environmental contamination and cross–transmission. Although authors control program was not successful in ending the outbreak, they think that their experience provides useful guidance for future approaches to this problem. read more
Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia
Clemens EC et al. – The treatment outcomes were similar regardless of vancomycin minimum inhibitory concentration (VAN MIC), although there was a non–statistically significant trend towards decreased clinical efficacy among patients with VAN MIC = 2 mg/L. Optimization of VAN pharmacokinetic indices did not appear to correlate with clinical responses. read more
Super-Bug News is available free of charge. Sign Up today and get your password for unrestricted use.
